Abstract 121P
Background
Compound EGFR mutations are a rare and heterogeneous subtype of non-small cell lung cancer (NSCLC). Currently there is no clear recommendation regarding the best therapeutic strategy to treat these patients. Chemotherapy, tyrosine kinase inhibitors (TKIs) and immunotherapies are often used as first or second line of treatment. Recently, a structure-based classification of EGFR mutations showed a novel and promising way of predicting response to treatment (Robichaux JC, Nature 2021).
Methods
We conducted a multicenter, retrospective, nationwide study of patients with metastatic NSCLC harboring compound EGFR mutations. The common mutation T790M and exon 20 insertions were excluded. Point mutation within exon 20 were included. Compound EGFR mutations were classified into two main groups according to structure-based classification: group 1 for classical mutations and group 2 for PACC (P-loop and αC-helix compressing) mutation. Clinical data were collected.
Results
We enrolled 47 patients in the analysis.16 patients were included in “classical mutations” group, 25 patients in the PACC group and 6 patients could not be classified. The median overall survival of the population was 37.2 m. [27-53.5]. The median progression free survival in the first-line setting (PFS1L) was shorter in the chemotherapy group (3.7 m.; 95% CI [3-NA]) than in the TKI group (11.2 m.; 95% CI [7.4-17], p=0.004). The median PFS1L was significantly longer in all TKI groups taken individually vs chemotherapy (1G TKI, 7.4 m., 95% CI [4.9-27.4]; afatinib, 13.2 m., 95% CI [7.5-NA]; osimertinib, 10.3 m., 95% CI [8.6-NA]; p=0.04). The median PFS2L treatment was significantly shorter in patients treated with chemotherapy (4 m. 95% CI [3.0-8.6]) compared to osimertinib (8.8 m. 95% CI [7.1-NA], p=0.01). According to structure-based classification, median PFS1L to afatinib was 10.1 m. for classical mutations group vs. 17 m. for the PACC mutations group with, p=0.09.
Conclusions
This study shows that treatment with TKIs in either first or second line is associated with favorable outcome in patients presenting compound EGFR mutation. Structure-based configuration of EGFR compound mutation might also be considered for selecting TKI in first line.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
CHU Toulouse.
Funding
Has not received any funding.
Disclosure
M. Duruisseaux: Financial Interests, Institutional, Research Grant: Pfizer, Novartis; Financial Interests, Personal, Advisory Board: Pfizer, Boehringer Ingelheim, AstraZeneca, Roche, BMS.C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen, Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen, Amgen. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Personal, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Personal, Other, Family member is an employee: AstraZeneca. J. Mazieres: Financial Interests, Personal, Advisory Board: BMS, MSD, AstraZeneca, Roche, Pfizer; Financial Interests, Institutional, Research Grant: Roche, BMS, AstraZeneca, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract